title: The adverse effects of preoperative cholangitis on the outcome of portal vein embolization and subsequent major hepatectomies.
abstract: BACKGROUND
  The presence of cholangitis has been shown to impair liver regeneration capacity after major hepatectomy in a rat cholangitis model. It is unclear, however, whether the presence of cholangitis has any impact on liver generation in clinical settings.
  
  
  OBJECTIVE
  To determine the effects of preoperative cholangitis on hepatic regeneration rates after preoperative portal vein embolizations (PVEs) and postoperative courses after major hepatectomies in humans.
  
  
  METHODS
  From 1991 to 2012, 450 patients underwent preoperative PVEs and subsequent major hepatectomies. Among them, 72 patients (16.0%) had preoperative cholangitis. The volume change of the nonembolized lobe after PVE and the postoperative outcomes after a major hepatectomy were compared between cholangitis and noncholangitis groups.
  
  
  RESULTS
  The average volume increase in the nonembolized lobe after PVE was almost identical in both the cholangitis (10.0%) and noncholangitis (9.5%) groups. The average term required to acquire institutional safety criteria, however, was longer in the cholangitis group (24.3 days) compared with the noncholangitis group (18.3 days) (P < .001). The postoperative maximum serum total bilirubin levels (5.7 mg/dL vs 8.1 mg/dL, P = .035), morbidity rate (56% vs 78%, P = .001), and postoperative hospital stay (44 days vs 53 days, P = .021) were all greater in the cholangitis group compared with the noncholangitis group. With multivariate logistic regression analyses, the presence of preoperative cholangitis was identified as one of the independent risk factors for postoperative morbidity.
  
  
  CONCLUSIONS
  These results indicate that patients with preoperative cholangitis should be carefully managed during their perioperative periods of PVE and after major hepatectomies.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Yokoyama
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Ebata
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Igami
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Gen
authors.initials: G
authors.lastname: Sugawara
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Mizuno
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: nagino@med.nagoya-u.ac.jp.
authors.forename: Masato
authors.initials: M
authors.lastname: Nagino
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002761:Cholangitis / Q000503:physiopathology*; D004621:Embolization, Therapeutic; D005260:Female; D006498:Hepatectomy / Q000401:mortality*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008115:Liver Regeneration; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D011184:Postoperative Period; D012189:Retrospective Studies; D016896:Treatment Outcome